• Home
  • Search Results
  • Metabolism of Babesia parasites in vitro. Comparison of several zwitterion buffers for the in vitro incubation of Babesia rodhaini.

Metabolism of Babesia parasites in vitro. Comparison of several zwitterion buffers for the in vitro incubation of Babesia rodhaini.

The Australian journal of experimental biology and medical science (1982-04-01)
D N Barry
ABSTRACT

The effect on the haemoprotozoan parasite Babesia rodhaini of adding a zwitterion buffer, HEPES, to a basal medium was studied by comparing the glucose uptake, ATP concentration, medium pH and infectivity of parasitized rat erythrocytes every 4 h during 24 h incubation in either Krebs Ringer phosphate (KRP) or KRP plus 28 mM HEPES. KRP plus HEPES was found to be superior to KRP for the maintenance of glucose uptake, erythrocyte ATP concentration, medium pH and infectivity of the parasite. Having established that HEPES improved the basal KRP medium, HEPES was then compared to three other buffers TES, BES and TRIS, to determine their relative effects on B. rodhaini during 18 h of incubation. At 28 and 56 mM concentration there was no significant difference in glucose uptake or lactate production among the 4 buffers. However, TES maintained the medium pH best, and BES preserved the infectivity of the parasite best. Further comparison of TES and BES at 10, 20, 30 and 40 mM established 50 mM TES to be best for buffering the pH of the medium and maintaining infectivity of B. rodhaini.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
BES, ≥99.0% (titration)
Sigma-Aldrich
BES, BioPerformance Certified, suitable for cell culture, ≥99.0%
Sigma-Aldrich
BES, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
BES, BioXtra, for molecular biology, ≥99.5% (T)

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.